1 / 36

Lecture 5 Enzymatic destruction (ESBL) Enzymatic modification ( erm )

Lecture 5 Enzymatic destruction (ESBL) Enzymatic modification ( erm ). Mechanisms of resistance. Modifying enzymes erm Degrading enzymes ESBL Target Change Efflux pumps. ESBL. Extendened Spectrum β -lactamases. Resistance in Gram negative bacteria.

mort
Download Presentation

Lecture 5 Enzymatic destruction (ESBL) Enzymatic modification ( erm )

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Lecture 5Enzymatic destruction (ESBL)Enzymatic modification (erm )

  2. Mechanisms of resistance • Modifying enzymes • erm • Degrading enzymes • ESBL • Target Change • Efflux pumps

  3. ESBL Extendened Spectrum β-lactamases

  4. Resistance in Gram negative bacteria • β-lactamases – the most important mechanism of resistance to β-lactam Ab (in Gr-). • ESBLs (Extended spectrum β-lactamases) • Carbapenemase

  5. V. cholerae C. jejuni Helicobacter pylori Acinetobacter spp. Gram Negative Rods/Bacilli (GNR) Many other (H. influenza, etc..) Stenotrophomonas maltophilia Pseudomonas aeruginosa Enterobacteriaceae

  6. Enterobactericea(E. coli, Klebsiela, Enterobacter) • Gram negative rods • Colonize GI tract • Clinical manifestations: • Urinary tract infections • Nosocomial pneumoniae • Bacteremia / Sepsis • Other

  7. β-lactamases Mechanism of resistance Enzymes that inactivate β -lactams by hydrolyzing the amide bond of the β -lactam ring.

  8. β-lactamase inhibitors • Clavulonic acid: derived from Streptomyces clavuligerus • Little antibiotic effect in itself • Given in combination with a β -lactam Ab • Function: by binding the β -lactamase enzyme more efficiently than the actual β -lactam • Thus protect the β -lactam Ab from hydrolysis • Not efficient against cephalosporinases

  9. 1950 1960 1970 1980 1990 2000 History of GNR resistance 1965 Broad spectrum β–lactamases (TEM-1 in E. coli) ESBL outbreaks in France 1940 Penicillinase detected in E. coli 1983 Extended spectrum β-lactamases TEM-1 widespread Carbapenemases 1964 Cefalotin use 1941 Penicillin use Early 1980s 3rd generation ceph. 1959 β-lactamase resistant penicillins: Methicillin 1985 Carbapenem (Imipenem) 1960s Broad spectrum/ extended spectrum penicillins 1976 β–lactamases inhibitors 2005 Tigecycline 1928 Fleming

  10. Molecular class: A: TEM SHV other B: Metalloenzymes (carbapenemases) C: Prototype: chromosomal ampC D: OXA (oxacillin hydrolyzing enzymes) Enzyme type (by substrate profile): Penicillinase Broad-spectrum Extended Spectrum Carbapenemase Genetic classification: plasmids mediated Chromosomal β-lactamases classification http://www.lahey.org/studies/webt.asp

  11. β-lactamases Penicillinase: gene blaZ , inducible, on transposon (can move between chromosome and plasmid). Broad spectrum β-lactamases (plasmid encoded) TEM SHV OXA (mainly in pseudomonas) ESBLs TEM related SHV related OXA related CTX-M Other ampCβ-lactamases Resistant to β-lactamase inhibitors chromosomal Carbapenemases Metallo- β-lactamases Serine carbapenemases Types of β-lactamases

  12. Broad spectrum b-lactamase (blaTEM) ESBL (TEM related) & & Mutation Plasmid transfer Genetic Mechanism Penicillinase blaZ Transformation

  13. ESBL • Confer resistance to 1st , 2nd, 3rd cef. • Most are susceptible to β-lactamase inhibitors • Most are susceptible to 4th cef. • All are susceptible to carbapenems • Diversity of ESBL • SHV (widespread) • TEM (>100 types) • OXA • Predominantly in Pseudomonas • less susceptible to β-lactamase inhibitors • CTX-M • Probably independent evolution • Highly resistant to 3rd generation cephalosporines • initially in South America, Far East & Eastern Europe • Probably most frequent worldwide • Clonal spread has been documented

  14. CarbapenemasesPan-resistance • Carbapenem: “the magic bullet” very broad spectrum • Metallo-β-lactamases (class B) • Not susceptible to clavulonate • Serine-carbapenemases (class A+ D) • KPC (Klebsiela pneumonia carbapenemase)- plasmid associated

  15. AmpCβ-lactamase • Chromosomal • Inducible • Fully resistant to β-lactamase inhibitors

  16. Further complicating matters: • More than one gene of β-lactamase / ESBL / ampC / carbapenemase can be carried on the same plasmid. • Genes of ESBL are carried on plasmids that usually carry additional resistant genes: frequently MDR • Laboratory diagnosis confusing: susceptibility profiles sometimes misleading: “hidden resistance” -> CLSI guidelines are changing. • CTX-M clones appearing in the community (Canada, Greece, Spain, Italy).

  17. Penicillins Cephalosporines (1st, 2nd) Extended spectrum Cephalosporines (3rd, 4th) Quinolones β-lactam-β-lactamase inhibitors Carbapenems Colistin…Tigecycline β-lactamase (penicillinase) Broad spectrum β -lactamase ESBL Quinolone resistance ESBL (OXA) ampC Carbapenemases Treatment of Gram negative infections: • We are running out of treatment options!

  18. The evolution of ESBL • In a single patient: • SHV-1-> 3rd Cef Rx. -> SHV-8 • ESBL TEM-24 from: Enterobacter aerogenes -> E. coli -> proteus mirabilis -> Pseudomonas aeruginosa • Mutations + efficient horizontal transmission • K. pneumoniae the major ESBL producer

  19. Klebsiela resistant to 3rd generation cephalosporines (CDC)

  20. MDR (qnl, aminoglycoside 3rd ceph.) in Klebsiella pneumoniae in Europe (EARSS) 2005

  21. Risk factors • Critically ill patients • Long hospitalization (median 11-67 d) • Invasive medical devices • Heavy Ab treatment • 3rd generation cephalosporines • Also other: quinolones, TMP-SMX, aminoglycosides, metronidazole

  22. Monoclonal Indicates transmission from patient to patient. Probably induced by lack of IC measures Infection Control Polyclonal Indicates multiple events of evolving resistance. Probably induced by selective Ab pressure Antibiotic control Control of ESBL outbreaks

  23. Enzymatic modification The case of macrolides

  24. Mechanism animation Enzymatic modification: • Aminoglycosides • Acetyltransferases • Phosphotransferases • nucleotidyltransferases • MLS (macrolides, lincosamides, streptogramin B) • erm (erythromycin resistance methylase) (most common) • Other: hydrolases, esterases, glycosylases, phosphotransferases, nucleotidyl-transferases and acetyltransferases

  25. Macrolide resistance • Macrolides are used to treat Gram+ bacteria and atypical bacteria (mycoplasma, legionella, chlamidia). • Bacteriostatic • Macrolides act by inhibiting protein synthesis, by binding to 50S subunit of the ribosome of the bacteria.

  26. Macrolide resistance • Phenotypes of macrolide resistance: • MLSB • M • Genotypes of macrolide resistance: • erm (erythromycin ribosomal methylase) • mef (specific macrolide effulx pump )

  27. ermErythromycin ribosomal methylase: • The predominant macrolide resistance mechanism. • 34 different classes of Erm proteins. • Each functions by methylating a single adenine residue of the 23S rRNA. • Methylation results in MLSB pheontype (resistance to most macrolides). • Can be either inducible or constitutive.

  28. Macrolide resistance inS. pneumoniae • ermB • predominant in most of the world • High level resistance (MIC>64) • mefA • most common in some areas (USA) • low level resistance (MIC 4-8) • Increasing level of resistance • Changing epidemiology • Strains containing both mefA + ermB emerging (from 10% to 18% in last 4 y) • mefA + ermB usually clonally related to MDR (19A – non-vaccine type) • Correlation between increasing consumption of mac and Mac R in SP

  29. Macrolide resistance in S. pneumoniae (2001-2005) / Flemingham et al. J. Infection

  30. 2000-2004

  31. PROTEKT US 2008 (2000-2004)

  32. Mac-R in S. pneumoniae in Finland /Bergman et al. 2006 AAC

  33. Macrolide resistance in GAS • Uncommon: US<5% • Single outbreak in Pittsburg (up to 48% Mac-R, single clone) • Mechanisms: • ermA (ErmA subclass TR) • ermB • mefA • All associated with mobile genetic elements

  34. Mac-R is GAS in Finland /Bergman et al. CID 2004

  35. Macrolide R in S. aureus • Clindamycin resistance – an important treatment issue. • Mechanism of resistance: • Target modification (MLSBi) (ermA, ermC) • Efflux pumps (MS phenotype: not clinda R) (msrA) • Inactivation

More Related